The mission of the Children's Oncology Group (COG) Phase 1/Pilot Consortium is to identify and develop effective new agents for children and adolescents with cancer, through rational and efficient clinical and laboratory research. Consortium clinical trials employ correlative pharmacological, biologic, and imaging studies to further the understanding of the disposition and action of new agents introduced into the treatment of children with cancer. The Consortium's primary specific aims are as follows: 1) To perform phase 1 trials of agents that target specific tumor types based on available data from tumor model systems, known molecular targets, and adult clinical trial data. 2) To develop agents that have additive or synergistic activity when combined with current cytotoxic chemotherapeutic agents, that modulate the antitumor or toxic effects of conventional anticancer drugs, or that provide a more efficacious or less toxic alternative to current chemotherapeutic agents. 3) To perform pilot trials that incorporate novel agents or combinations of agents, or that incorporate pharmacologic or biologic endpoints to enhance our understanding of the new agents and their effect on the tumor, in selected tumor types based on available data from tumor model systems, the molecular profile of the tumor, and pediatric phase 1 and 2 trial data. Advances made in the treatment of childhood malignancies over the past four decades have resulted in overall cure rates of approximately 80%. Despite these advances, several childhood cancers still have unacceptably low cure rates. Furthermore, even when treatment is successful, the acute and long-term morbidity of current therapy can be substantial. Agents targeting critical signaling pathways in the malignant process now have an established role in the treatment of select adult cancers. Development of targeted therapy for childhood cancer offers the prospect of more efficacious and less toxic therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA097452-09
Application #
7905979
Study Section
Subcommittee G - Education (NCI)
Program Officer
Smith, Malcolm M
Project Start
2002-08-08
Project End
2012-07-31
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
9
Fiscal Year
2010
Total Cost
$3,476,954
Indirect Cost
Name
National Childhood Cancer Foundation
Department
Type
DUNS #
624124301
City
Arcadia
State
CA
Country
United States
Zip Code
91006
London, Wendy B; Bagatell, Rochelle; Weigel, Brenda J et al. (2017) Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. Cancer 123:4914-4923
Leary, Sarah E S; Park, Julie R; Reid, Joel M et al. (2017) Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res 23:6062-6069
Rheingold, Susan R; Tasian, Sarah K; Whitlock, James A et al. (2017) A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114). Br J Haematol 177:467-474
Mossé, Yael P; Voss, Stephan D; Lim, Megan S et al. (2017) Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol 35:3215-3221
Burke, Michael J; Ahern, Charlotte; Weigel, Brenda J et al. (2015) Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. Pediatr Blood Cancer 62:743-50
Voss, Stephan D; Glade-Bender, Julia; Spunt, Sheri L et al. (2015) Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium. Pediatr Blood Cancer 62:45-51
Shiroishi, Mark S; Panigrahy, Ashok; Moore, Kevin R et al. (2015) Combined MRI and MRS improves pre-therapeutic diagnoses of pediatric brain tumors over MRI alone. Neuroradiology 57:951-6
Fouladi, Maryam; Perentesis, John P; Wagner, Lars M et al. (2015) A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res 21:1558-65
Moorthy, Ganesh S; Norris, Robin E; Adamson, Peter C et al. (2014) A liquid chromatography/tandem mass spectrometry method for determination of obatoclax in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 971:30-4
Weigel, Brenda; Malempati, Suman; Reid, Joel M et al. (2014) Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer 61:452-6

Showing the most recent 10 out of 59 publications